Comparing venlafaxine extended release and fluoxetine for preventing the recurrence of major depression: Results from the PREVENT study

Michael E. Thase, Alan Gelenberg, Susan G. Kornstein, James H. Kocsis, Madhukar H. Trivedi, Philip Ninan, Thomas Li, Ron Pedersen, Martin Keller

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

This secondary analysis from the Prevention of Recurrent Episodes of Depression with Venlafaxine Extended Release (ER) for Two Years (PREVENT) study compared the efficacy of venlafaxine ER and fluoxetine for the prevention of recurrence in patients with a history of recurrent major depressive disorder (MDD). Patients received double-blind treatment with venlafaxine ER (75-300 mg/d) or fluoxetine (20-60 mg/d) for 10 weeks (acute phase). Responders (17-item Hamilton Rating Scale for Depression [HAM-D17] score ≤12 and ≥50% reduction from baseline) continued on the same treatment during the 6-month continuation phase. At the start of the first and second 12-month maintenance phases, venlafaxine ER responders were randomly assigned to receive venlafaxine ER or placebo, whereas patients receiving fluoxetine continued to receive fluoxetine throughout both maintenance phases. The primary outcome was time to recurrence (HAM-D17 > 12, reduction in HAM-D17 score ≤ 50% from acute baseline, and meeting DSM-IV criteria for a diagnosis of MDD), which was assessed using Kaplan-Meier estimates. Using the primary definition of recurrence, the estimated probability of not experiencing a recurrence was 71.9% for venlafaxine ER (n  160) and 55.8% for fluoxetine (n  99) across 24 months of maintenance treatment. For this primary analysis, the overall effect of venlafaxine ER treatment was not statistically significant (p  0.399) compared with fluoxetine; however, a significant treatment-by-time interaction was observed (p  0.034). No significant between-group differences were observed with any of the secondary efficacy variables. Venlafaxine ER and fluoxetine were similarly well tolerated across 2 years of maintenance-phase therapy.

Original languageEnglish (US)
Pages (from-to)412-420
Number of pages9
JournalJournal of Psychiatric Research
Volume45
Issue number3
DOIs
StatePublished - Mar 2011

Fingerprint

Fluoxetine
Depression
Recurrence
Maintenance
Major Depressive Disorder
Therapeutics
Venlafaxine Hydrochloride
Kaplan-Meier Estimate
Secondary Prevention
Diagnostic and Statistical Manual of Mental Disorders
Placebos

Keywords

  • Fluoxetine
  • Major depressive disorder
  • PREVENT study
  • Venlafaxine extended release

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Comparing venlafaxine extended release and fluoxetine for preventing the recurrence of major depression : Results from the PREVENT study. / Thase, Michael E.; Gelenberg, Alan; Kornstein, Susan G.; Kocsis, James H.; Trivedi, Madhukar H.; Ninan, Philip; Li, Thomas; Pedersen, Ron; Keller, Martin.

In: Journal of Psychiatric Research, Vol. 45, No. 3, 03.2011, p. 412-420.

Research output: Contribution to journalArticle

Thase, Michael E. ; Gelenberg, Alan ; Kornstein, Susan G. ; Kocsis, James H. ; Trivedi, Madhukar H. ; Ninan, Philip ; Li, Thomas ; Pedersen, Ron ; Keller, Martin. / Comparing venlafaxine extended release and fluoxetine for preventing the recurrence of major depression : Results from the PREVENT study. In: Journal of Psychiatric Research. 2011 ; Vol. 45, No. 3. pp. 412-420.
@article{8c6b846e3891422f87a0268de2230b98,
title = "Comparing venlafaxine extended release and fluoxetine for preventing the recurrence of major depression: Results from the PREVENT study",
abstract = "This secondary analysis from the Prevention of Recurrent Episodes of Depression with Venlafaxine Extended Release (ER) for Two Years (PREVENT) study compared the efficacy of venlafaxine ER and fluoxetine for the prevention of recurrence in patients with a history of recurrent major depressive disorder (MDD). Patients received double-blind treatment with venlafaxine ER (75-300 mg/d) or fluoxetine (20-60 mg/d) for 10 weeks (acute phase). Responders (17-item Hamilton Rating Scale for Depression [HAM-D17] score ≤12 and ≥50{\%} reduction from baseline) continued on the same treatment during the 6-month continuation phase. At the start of the first and second 12-month maintenance phases, venlafaxine ER responders were randomly assigned to receive venlafaxine ER or placebo, whereas patients receiving fluoxetine continued to receive fluoxetine throughout both maintenance phases. The primary outcome was time to recurrence (HAM-D17 > 12, reduction in HAM-D17 score ≤ 50{\%} from acute baseline, and meeting DSM-IV criteria for a diagnosis of MDD), which was assessed using Kaplan-Meier estimates. Using the primary definition of recurrence, the estimated probability of not experiencing a recurrence was 71.9{\%} for venlafaxine ER (n  160) and 55.8{\%} for fluoxetine (n  99) across 24 months of maintenance treatment. For this primary analysis, the overall effect of venlafaxine ER treatment was not statistically significant (p  0.399) compared with fluoxetine; however, a significant treatment-by-time interaction was observed (p  0.034). No significant between-group differences were observed with any of the secondary efficacy variables. Venlafaxine ER and fluoxetine were similarly well tolerated across 2 years of maintenance-phase therapy.",
keywords = "Fluoxetine, Major depressive disorder, PREVENT study, Venlafaxine extended release",
author = "Thase, {Michael E.} and Alan Gelenberg and Kornstein, {Susan G.} and Kocsis, {James H.} and Trivedi, {Madhukar H.} and Philip Ninan and Thomas Li and Ron Pedersen and Martin Keller",
year = "2011",
month = "3",
doi = "10.1016/j.jpsychires.2010.07.009",
language = "English (US)",
volume = "45",
pages = "412--420",
journal = "Journal of Psychiatric Research",
issn = "0022-3956",
publisher = "Elsevier Limited",
number = "3",

}

TY - JOUR

T1 - Comparing venlafaxine extended release and fluoxetine for preventing the recurrence of major depression

T2 - Results from the PREVENT study

AU - Thase, Michael E.

AU - Gelenberg, Alan

AU - Kornstein, Susan G.

AU - Kocsis, James H.

AU - Trivedi, Madhukar H.

AU - Ninan, Philip

AU - Li, Thomas

AU - Pedersen, Ron

AU - Keller, Martin

PY - 2011/3

Y1 - 2011/3

N2 - This secondary analysis from the Prevention of Recurrent Episodes of Depression with Venlafaxine Extended Release (ER) for Two Years (PREVENT) study compared the efficacy of venlafaxine ER and fluoxetine for the prevention of recurrence in patients with a history of recurrent major depressive disorder (MDD). Patients received double-blind treatment with venlafaxine ER (75-300 mg/d) or fluoxetine (20-60 mg/d) for 10 weeks (acute phase). Responders (17-item Hamilton Rating Scale for Depression [HAM-D17] score ≤12 and ≥50% reduction from baseline) continued on the same treatment during the 6-month continuation phase. At the start of the first and second 12-month maintenance phases, venlafaxine ER responders were randomly assigned to receive venlafaxine ER or placebo, whereas patients receiving fluoxetine continued to receive fluoxetine throughout both maintenance phases. The primary outcome was time to recurrence (HAM-D17 > 12, reduction in HAM-D17 score ≤ 50% from acute baseline, and meeting DSM-IV criteria for a diagnosis of MDD), which was assessed using Kaplan-Meier estimates. Using the primary definition of recurrence, the estimated probability of not experiencing a recurrence was 71.9% for venlafaxine ER (n  160) and 55.8% for fluoxetine (n  99) across 24 months of maintenance treatment. For this primary analysis, the overall effect of venlafaxine ER treatment was not statistically significant (p  0.399) compared with fluoxetine; however, a significant treatment-by-time interaction was observed (p  0.034). No significant between-group differences were observed with any of the secondary efficacy variables. Venlafaxine ER and fluoxetine were similarly well tolerated across 2 years of maintenance-phase therapy.

AB - This secondary analysis from the Prevention of Recurrent Episodes of Depression with Venlafaxine Extended Release (ER) for Two Years (PREVENT) study compared the efficacy of venlafaxine ER and fluoxetine for the prevention of recurrence in patients with a history of recurrent major depressive disorder (MDD). Patients received double-blind treatment with venlafaxine ER (75-300 mg/d) or fluoxetine (20-60 mg/d) for 10 weeks (acute phase). Responders (17-item Hamilton Rating Scale for Depression [HAM-D17] score ≤12 and ≥50% reduction from baseline) continued on the same treatment during the 6-month continuation phase. At the start of the first and second 12-month maintenance phases, venlafaxine ER responders were randomly assigned to receive venlafaxine ER or placebo, whereas patients receiving fluoxetine continued to receive fluoxetine throughout both maintenance phases. The primary outcome was time to recurrence (HAM-D17 > 12, reduction in HAM-D17 score ≤ 50% from acute baseline, and meeting DSM-IV criteria for a diagnosis of MDD), which was assessed using Kaplan-Meier estimates. Using the primary definition of recurrence, the estimated probability of not experiencing a recurrence was 71.9% for venlafaxine ER (n  160) and 55.8% for fluoxetine (n  99) across 24 months of maintenance treatment. For this primary analysis, the overall effect of venlafaxine ER treatment was not statistically significant (p  0.399) compared with fluoxetine; however, a significant treatment-by-time interaction was observed (p  0.034). No significant between-group differences were observed with any of the secondary efficacy variables. Venlafaxine ER and fluoxetine were similarly well tolerated across 2 years of maintenance-phase therapy.

KW - Fluoxetine

KW - Major depressive disorder

KW - PREVENT study

KW - Venlafaxine extended release

UR - http://www.scopus.com/inward/record.url?scp=79953846623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953846623&partnerID=8YFLogxK

U2 - 10.1016/j.jpsychires.2010.07.009

DO - 10.1016/j.jpsychires.2010.07.009

M3 - Article

C2 - 20801464

AN - SCOPUS:79953846623

VL - 45

SP - 412

EP - 420

JO - Journal of Psychiatric Research

JF - Journal of Psychiatric Research

SN - 0022-3956

IS - 3

ER -